keyword
MENU ▼
Read by QxMD icon Read
search

Ki67 breast cancer

keyword
https://www.readbyqxmd.com/read/28923573/neoadjuvant-buparlisib-plus-trastuzumab-and-paclitaxel-for-women-with-her2-primary-breast-cancer-a-randomised-double-blind-placebo-controlled-phase-ii-trial-neophoebe
#1
Sibylle Loibl, Lorena de la Pena, Valentina Nekljudova, Dimitrios Zardavas, Stefan Michiels, Carsten Denkert, Mahdi Rezai, Begoña Bermejo, Michael Untch, Soo Chin Lee, Sabine Turri, Patrick Urban, Sherko Kümmel, Guenther Steger, Andrea Gombos, Michael Lux, Martine J Piccart, Gunter Von Minckwitz, José Baselga, Sherene Loi
AIM: The Neoadjuvant PI3K inhibition in HER2 OverExpressing Breast cancEr (NeoPHOEBE) trial evaluated the efficacy and safety of buparlisib, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, plus trastuzumab and paclitaxel as neoadjuvant treatment for human epidermal growth factor receptor-2 positive (HER2+) breast cancer. METHODS: NeoPHOEBE was a neoadjuvant, phase II, randomised, double-blind study. Women with HER2+ breast cancer were randomised within two independent cohorts by PIK3CA mutation status and, in each cohort stratified by oestrogen receptor (ER) status to receive buparlisib or placebo plus trastuzumab (first 6 weeks) followed by buparlisib or placebo with trastuzumab and paclitaxel...
September 15, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28915617/predictive-factors-of-pathologic-complete-response-in-her2-positive-and-axillary-lymph-node-positive-breast-cancer-after-neoadjuvant-paclitaxel-carboplatin-plus-with-trastuzumab
#2
Jinhua Ding, Yinlong Yang, Li Jiang, Weizhu Wu, Zhiming Shao
OBJECTIVE: This study was performed to investigate the proportion as well as the predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab (PCH). RESULTS: The pCR rate in the breast, axilla and both was 44.3% (39/88), 47.7% (42/88) and 34.1% (30/88), respectively. Patients with and without pCR were similar in term of age, BMI, menstrual status, family history, treatment cycles and tumor characteristics (laterality and size of tumor)...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28915312/dce-and-dw-mri-as-early-imaging-biomarkers-of-treatment-response-in-a-preclinical-model-of-triple-negative-breast-cancer
#3
Stephanie L Barnes, Anna G Sorace, Jennifer G Whisenant, J Oliver McIntyre, Hakmook Kang, Thomas E Yankeelov
This work evaluates quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted MRI (DW-MRI) parameters as early biomarkers of response in a preclinical model of triple negative breast cancer (TNBC). The standard Tofts' model of DCE-MRI returns estimates of the volume transfer constant (K(trans) ) and the extravascular extracellular volume fraction (ve ). DW-MRI returns estimates of the apparent diffusion coefficient (ADC). Mice (n = 38) were injected subcutaneously with MDA-MB-231...
September 15, 2017: NMR in Biomedicine
https://www.readbyqxmd.com/read/28903367/exploratory-investigation-of-psca-protein-expression-in-primary-breast-cancer-patients-reveals-a-link-to-her2-neu-overexpression
#4
Theresa Link, Friederike Kuithan, Armin Ehninger, Jan Dominik Kuhlmann, Michael Kramer, Andreas Werner, Axel Gatzweiler, Barbara Richter, Gerhard Ehninger, Gustavo Baretton, Michael Bachmann, Pauline Wimberger, Katrin Friedrich
BACKGROUND: Prostate stem cell antigen (PSCA) has been suggested as biomarker and therapeutic target for prostate cancer. Recent advances showed that PSCA is up-regulated in other cancer entities, such as bladder or pancreatic cancer. However, the clinical relevance of PSCA-expression in breast cancer patients has not yet been established and is therefore addressed by the current study. METHODS: PSCA-protein expression was assessed in 405 breast cancer patients, using immunohistochemistry (PSCA antibody MB1) and tissue microarrays...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28899737/expression-of-yes-associated-protein-yap-and-its-clinical-significance-in-breast-cancer-tissues
#5
Lanqing Cao, Ping-Li Sun, Min Yao, Meng Jia, Hongwen Gao
The transcriptional co-activator YES-associated protein (YAP) has been reported to act as both an oncogene and tumor suppressor in breast cancers. In this study, we evaluated YAP expression immunohistochemically in 324 breast cancer tissues and correlated the expression with clinicopathological findings and patient survival data. Additionally, we reviewed the literature to clarify the role of YAP in breast cancer. We detected YAP, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth receptor-2 (HER2) expression and a Ki67 labeling index >20% in 53...
September 9, 2017: Human Pathology
https://www.readbyqxmd.com/read/28892021/near-infrared-triggered-photodynamic-therapy-toward-breast-cancer-cells-using-dendrimer-functionalized-upconversion-nanoparticles
#6
Bing-Yen Wang, Ming-Liang Liao, Guan-Ci Hong, Wen-Wei Chang, Chih-Chien Chu
Water-soluble upconversion nanoparticles (UCNPs) that exhibit significant ultraviolet, blue, and red emissions under 980-nm laser excitation were successfully synthesized for performing near infrared (NIR)-triggered photodynamic therapy (PDT). The lanthanide-doped UCNPs bearing oleate ligands were first exchanged by citrates to generate polyanionic surfaces and then sequentially encapsulated with NH₂-terminated poly(amido amine) (PAMAM) dendrimers (G4) and chlorine6 (Ce6) using a layer-by-layer (LBL) absorption strategy...
September 11, 2017: Nanomaterials
https://www.readbyqxmd.com/read/28889189/prognostic-role-of-progesterone-receptor-expression-in-a-population-based-analysis
#7
Adele Caldarella, Alessandro Barchielli
PURPOSE: The role of progesterone (PR) expression in the management of breast cancer is controversial. The aim of this study is to evaluate the characteristics and prognosis of progesterone status among breast cancers patients in a population-based analysis. MATERIALS AND METHODS: Through the Tuscan Cancer Registry data on all the invasive breast cancer cases diagnosed during the period 2004-2005 in the provinces of Florence and Prato, central Italy, were retrieved...
September 9, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28886153/tumor-size-and-proliferative-marker-geminin-rather-than-ki67-expression-levels-significantly-associated-with-maximum-uptake-of-18f-deoxyglucose-levels-on-positron-emission-tomography-for-breast-cancers
#8
Arisa Nishimukai, Natsuko Inoue, Ayako Kira, Masashi Takeda, Koji Morimoto, Kazuhiro Araki, Kazuhiro Kitajima, Takahiro Watanabe, Seiichi Hirota, Toyomasa Katagiri, Shoji Nakamori, Kouhei Akazawa, Yasuo Miyoshi
It has been well established that maximum standardized uptake value (SUVmax) for 18F-fluorodeoxyglucose positron-emission tomography/computed tomography (FDG PET/CT) is clinically useful for evaluating treatment efficacy as well as predicting prognosis of breast cancer patients. Although SUVmax reflects increased glucose uptake and metabolism possibly induced by activation of growth factor signaling or TP53 dysfunction, tumor characteristics of SUVmax-high breast cancers remain to be elucidated. For the present study, we used immunohistochemical staining to investigate expressions of phospho-ribosomal protein S6 (pS6, downstream molecule of phosphatidyl inositol 3-kinase/Akt/mammalian target of the rapamycin/S6K pathway) and phosphor-p44/42 mitogen-activated protein kinase (pMAPK)...
2017: PloS One
https://www.readbyqxmd.com/read/28885584/morphological-evaluation-of-tumor-infiltrating-lymphocytes-tils-to-investigate-invasive-breast-cancer-immunogenicity-reveal-lymphocytic-networks-and-help-relapse-prediction-a-retrospective-study
#9
Gloria Romagnoli, Meike Wiedermann, Friederike Hübner, Antonia Wenners, Micaela Mathiak, Christoph Röcken, Nicolai Maass, Wolfram Klapper, Ibrahim Alkatout
Tumor-infiltrating lymphocytes (TILs) in breast cancer are a key representative of the tumor immune microenvironment and have been shown to provide prognostic and predictive biomarkers. The extent of lymphocytic infiltration in tumor tissues can be assessed by evaluating hematoxylin and eosin (H&E)-stained tumor sections. We investigated tissue microarrays of 31 invasive breast cancer patients, looking at quantity and topological distribution of CD3+, CD8+, CD20+, Ki67+, FoxP3+ TILs and CD3+/FoxP3+, CD8+/FoxP3+ cell ratios...
September 8, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28876586/is-ki67-predictive-of-tumour-response-to-neoadjuvant-chemotherapy-and-to-long-term-disease-outcome-in-breast-cancer-patients-at-dr-george-mukhari-academic-hospital-a-preliminary-report
#10
D Mokone, B Ratlabala, M Z Koto, J H R Becker, M Bida
BACKGROUND: The difference in tumour response to neoadjuvant chemotherapy has been attributed to difference in tumour biology. Ki67, a proliferative protein, is one of the molecular markers that are used to predict tumour response to chemotherapy. A high Ki67 index and or a decrease in Ki67 index after a short-term of NAC is said to predict clinical and pathological response and thus disease free survival but not over-all survival. METHOD: A prospective study. Core needle biopsy is repeated after 2 cycles of NAC (8 weeks) in Stage IIb and Stage III breast cancer patients and is compared to base-line biopsy...
September 2017: South African Journal of Surgery. Suid-Afrikaanse Tydskrif Vir Chirurgie
https://www.readbyqxmd.com/read/28874413/a-phase-ii-trial-of-neoadjuvant-mk2206-an-akt-inhibitor-with-anastrozole-in-clinical-stage-2-or-3-pik3ca-mutant-er%C3%A2-positive-and-her2-negative-breast-cancer
#11
Cynthia X Ma, Vera Suman, Matthew P Goetz, Donald W Northfelt, Mark E Burkard, Foluso Ademuyiwa, Michael J Naughton, Julie Margenthaler, Rebecca Aft, Richard J Gray, Amye J Tevaarwerk, Lee G Wilke, Tufia C Haddad, Timothy Moynihan, Charles Loprenzi, Tina Hieken, Erica K Barnell, Zachary L Skidmore, Yan-Yang Feng, Kilannin Krysiak, Jeremy Hoog, Zhanfang Guo, Leslie Nehring, Kari B Wisinski, Elaine R Mardis, Ian S Hagemann, Kiran Vij, Souzan Sanati, Hussam Al-Kateb, Obi L Griffith, Malachi Griffith, Austin Doyle, Charles Erlichman, Matthew J Ellis
PURPOSE: Hyper-activation of AKT is common and associated with endocrine resistance in estrogen receptor positive (ER+) breast cancer. The allosteric pan-AKT inhibitor MK-2206 induced apoptosis in PIK3CA mutant ER+ breast cancer under estrogen-deprived condition in preclinical studies. This neoadjuvant phase II trial was therefore conducted to test the hypothesis that adding MK-2206 to anastrozole induces pathologic complete response (pCR) in PIK3CA mutant ER+ breast cancer. EXPERIMENTAL DESIGN: Potential eligible patients with clinical stage II/III ER+/HER2- breast cancer were pre-registered and received anastrozole (goserelin if premenopausal) for 28 days in cycle 0 pending tumor PIK3CA sequencing...
September 5, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28872974/the-postoperative-immunosuppressive-phenotypes-of-peripheral-t-helper-cells-are-associated-with-poor-prognosis-of-breast-cancer-patients
#12
Ganglan Fu, Liping Miao, Meng Wang, MingYan Guo, Chengli Wang, Fengtao Ji, Minghui Cao
PURPOSE: T helper cells play essential roles in anti-tumor immune response. However, the postoperative changes of peripheral T cell subsets and their clinical significance in breast cancer patients remain largely unknown. METHODS: We evaluated the perioperative changes of T lymphocyte subsets in invasive breast cancer (IBC) patients and breast fibroadenoma (BF) patients preoperatively (preop) and 6, 24, 72 hours postoperatively (POH6, POH24, and POH72). Proportions of CD3, CD4, CD8, T helper (Th) 1, Th2, Th17 cells, regulatory T cells (Treg), and CD4(+)/CD8(+), Th1/Th2 ratio were detected by flow cytometry...
October 2017: Immunological Investigations
https://www.readbyqxmd.com/read/28869790/evaluating-the-role-of-magnetic-resonance-imaging-post-neoadjuvant-therapy-for-breast-cancer-in-the-neonab-trial
#13
Caitlin Murphy, Violet Mukaro, Robert Tobler, Rebecca Asher, Emma Gibbs, Linda West, Bruno Giuffre, Sally Baron-Hay, Mustafa Khasraw
BACKGROUND: Magnetic Resonance Imaging (MRI) accuracy after neoadjuvant systemic therapy (NST) for breast cancer varies according to hormone receptor (HR), human epidermal growth factor receptor type-2 (HER2) subtype and Ki67 proliferation index. Whether MRI accuracy varies by genomic signatures is unknown. We examined accuracy of MRI in the NEONAB trial (Clinicaltrials.gov #: NCT01830244). METHODS: Patients with stage II-III breast cancer received sequential epirubicin, cyclophosphamide and nab-paclitaxel and trastuzumab if HER2+...
September 4, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/28865009/inverse%C3%A2-relationship-between-ki67-and-survival-in-early-luminal-breast-cancer-confirmation-in-a-multivariate-analysis
#14
Alberto Gallardo, Barbara Garcia-Valdecasas, Paola Murata, Rolando Teran, Laura Lopez, Agusti Barnadas, Enrique Lerma
INTRODUCTION: Ki67 is a prognostic marker in early breast cancer, but its real usefulness remains controversial. The standard cut-off values for Ki67 have not been universally accepted and different values may be used depending on the type of biopsy (fine needle biopsy versus surgical specimen biopsy). The objective of this study was to evaluate the prognostic significance of Ki67 and to determine the most accurate prognostic cut-off. MATERIALS AND METHODS: 495 tissue samples from patients with luminal tumours who underwent breast surgery between 2005 and 2011 were collected from the Department of Pathology at Hospital de la Santa Creu i Sant Pau, Barcelona...
September 1, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28863181/brca1-protein-expression-and-subcellular-localization-in-primary-breast-cancer-automated-digital-microscopy-analysis-of-tissue-microarrays
#15
Abeer M Mahmoud, Virgilia Macias, Umaima Al-Alem, Ryan J Deaton, Andre Kadjaksy-Balla, Peter H Gann, Garth H Rauscher
PURPOSE: Mutations in BRCA1 are associated with familial as well as sporadic aggressive subtypes of breast cancer, but less is known about whether BRCA1 expression or subcellular localization contributes to progression in population-based settings. METHODS: We examined BRCA1 expression and subcellular localization in invasive breast cancer tissues from an ethnically diverse sample of 286 patients and 36 normal breast tissue controls. Two different methods were used to label breast cancer tissues for BRCA1: (1) Dual immunofluoresent staining with BRCA1 and cytokeratin 8/18 and (2) immunohistochemical staining using the previously validated MS110 mouse monoclonal antibody...
2017: PloS One
https://www.readbyqxmd.com/read/28859899/combination-of-using-prodrug-modified-cationic-liposome-nanocomplexes-and-a-potentiating-strategy-via-targeted-co-delivery-of-gemcitabine-and-docetaxel-for-cd44-overexpressed-triple-negative-breast-cancer-therapy
#16
Yang Fan, Qingjie Wang, Guimei Lin, Yanbin Shi, Zili Gu, Tingting Ding
In this study, novel prodrug-modified cationic liposome nanocomplexes (Combo NCs) were reported for gemcitabine (GEM) and docetaxel (DTX) co-delivery. This nanoplatform exhibited multiple favorable characteristics, such as a 'green' fabrication with a one-step chemical reaction, appropriate size (∼ 200 nm) and distribution (PDI < 0.2), low zeta potential (-31.1 mv), high drug-loading efficiency (9.3% GEM plus 3.1% DTX, wt%) and pH and enzymatic dual-stimulus-responsive release properties. Immunofluorescence and cellular uptake studies showed that Combo NCs efficiently targeted overexpressed CD44 in MDA-MB-231 carcinoma...
August 28, 2017: Acta Biomaterialia
https://www.readbyqxmd.com/read/28859615/identification-of-predictive-markers-of-the-therapeutic-effect-of-eribulin-chemotherapy-for-locally-advanced-or-metastatic-breast-cancer
#17
Shinichiro Kashiwagi, Wakaba Fukushima, Yuka Asano, Wataru Goto, Koji Takada, Satoru Noda, Tsutomu Takashima, Naoyoshi Onoda, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira
BACKGROUND: The recently developed reagent, eribulin mesylate (eribulin), is a microtubule dynamics inhibitor with a mechanism of action that differs from those of taxanes and vinca alkaloids. This drug is considered to be a promising chemotherapeutic agent for the treatment of locally advanced or metastatic breast cancer (MBC). In this study, we investigated if variables such as tumor expression of β-tubulin class III, glutathione S-transferase pi (GSTP) 1 or transducin-like enhancer of split (TLE) 3 might act as predictive factors on the therapeutic effect of eribulin chemotherapy...
August 31, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28855848/primary-breast-angiosarcoma-a-rare-presentation-of-rare-tumor-case-report
#18
Fayçal Abbad, Najat Cherif Idrissi, Btissam Fatih, Bouchra Fakhir, Jamal Drissi, Mouna Khouchani, Hanane Rais
BACKGROUND: Primary breast angiosarcoma is defined as malignant proliferation showing endothelial differentiation. It is a very rare tumour (0.05% of primary mammary cancers), whose diagnosis can be difficult. CASE PRESENTATION: We report the observation of a patient with no previous history, aged 27 years. The clinical examination finds a right breast discreetly increased in volume. The trucut biopsy was in favour of a lactating tubular adenoma. However, an immunohistochemical complement was requested...
2017: BMC Clinical Pathology
https://www.readbyqxmd.com/read/28843709/pd-l1-in-breast-cancer-comparative-analysis-of-three-different-antibodies
#19
Tejashree Karnik, Bruce F Kimler, Fang Fan, Ossama Tawfik
The Programmed cell death-1 and its ligand-1 (PD-L1) interaction serve as a regulatory check against excessive immune response to antigen and autoimmunity. We compared the performance of three different PD-L1 antibodies (Ventana SP263, Dako 22C3 and BioCare RbMCAL10 antibodies) in 136 invasive ductal carcinoma specimens including 43 primary, 48 locally metastatic and 46 distantly metastatic disease. PD-L1 expression was correlated with clinicopathologic parameters including tumor size, grade, lymphovascular invasion, estrogen receptor (ER), progesterone receptor (PgR), HER2, Ki67, molecular type, TN status...
August 23, 2017: Human Pathology
https://www.readbyqxmd.com/read/28839123/predictive-value-of-clinicopathological-characteristics-for-sentinel-lymph-node-metastasis-in-early-breast-cancer
#20
Jinhua Ding, Li Jiang, Weizhu Wu
BACKGROUND Sentinel lymph node biopsy (SLNB) is one of the preferred treatments for breast cancer including clinically negative lymph node breast cancer. However, for 60-70% of patients this invasive axilla surgery is unnecessary. Our study aimed to identify the predictors for sentinel lymph node (SLN) metastasis in early breast cancer patients and provide evidence for rational decision-making in specified clinical situations. MATERIAL AND METHODS Medical records of 417 breast cancer patients who were treated with a breast surgical procedure and SLNB in Ningbo Medical Center Lihuili Eastern Hospital were retrospectively reviewed...
August 25, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
keyword
keyword
72753
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"